Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 9/20 | 0.48 |
| ▸ | HTR2B | P41595 | 9/20 | 0.48 |
| ▸ | HTR2A | P28223 | 7/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630938 | 0.81 | HTR2C (0.47) | HTR2CHTR2BHTR2A | |
| SCHEMBL3409778 | 0.79 | EPHX2 (0.58) | EPHX2HTR2CHTR2BHTR2ATRPV1 | |
| SCHEMBL4629662 | 0.79 | HTR2C (0.45) | HTR2CHTR2BHTR2AHSD11B1 | |
| SCHEMBL20555976 | 0.75 | EPHX2 (0.53) | EPHX2HTR2CHTR2BHTR2ATRPV1 | |
| SCHEMBL233710 | 0.73 | EPHX2 (1.00) | EPHX2TRPV1HSD11B1GAA | |
| Hydrochloric Acid SCHEMBL10319192 | 0.72 | EPHX2 (0.97) | EPHX2TRPV1HSD11B1GAA | |
| Piperazine SCHEMBL5324447 | 0.72 | EPHX2 (0.97) | EPHX2TRPV1HSD11B1GAA | |
| SCHEMBL4630341 | 0.71 | EPHX2 (0.47) | EPHX2HTR2CHTR2BHTR2ATRPV1 | |
| SCHEMBL5356587 | 0.69 | EPHX2 (0.89) | EPHX2TRPV1HSD11B1GAA | |
| SCHEMBL31419319 | 0.68 | EPHX2 (0.64) | EPHX2HSD11B1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2287162-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2287161-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | EPHX2 3735/4885HTR2C 11/4885HTR2B 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.